Trulieve Cannabis Corp. CEO Kim Rivers will be participating in the Alliance Global Partners Consumer Cannabis Virtual Conference and Canaccord Genuity Virtual US Cannabis Symposium

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the United States today announced that Trulieve’s CEO Kim Rivers will participate in Alliance Global Partners (A.G.P.) Consumer Cannabis Virtual Conference on September 29, 2020 . The virtual conference will consist of one-on-one meetings with leading global companies in the CBD and Cannabis industries.


In addition, Ms. Rivers is scheduled to give a live presentation with Canaccord Genuity’s Virtual US Cannabis Symposium at 9:00 a.m. EST on September ­­30, 2020. This one-day virtual conference will feature company presentations and one-on-one meetings with leading companies in the U.S. cannabis industry.

For more information about Trulieve’s upcoming investor events, please visit our website at: https://investors.trulieve.com/events-presentations

About Trulieve
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also operates in California , Massachusetts and Connecticut . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

To learn more about Trulieve, visit www.Trulieve.com .

The Canadian Securities Exchange has not reviewed, approved or disapproved the ‎content of this news release.‎

Forward-Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company and statements with regard to the Report and the Company’s response thereto. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

Cision View original content: http://www.prnewswire.com/news-releases/trulieve-ceo-kim-rivers-to-speak-at-two-upcoming-investor-conferences-301138998.html

SOURCE Trulieve Cannabis Corp.

News Provided by PR Newswire via QuoteMedia

  • Existing At-The-Market (ATM) program now complete
  • New Preliminary Base Shelf Prospectus Has Been Filed
  • Current Cash Position is Approximately $272 million

NYSE | TSX: ACB

Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed the previously filed At-The-Market (“ATM”) program. Because of this, the Company has filed a new preliminary short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada except Quebec and a corresponding shelf registration statement on Form F–10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).

Keep reading... Show less

 Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed an initial production run of all four of its Ayurvedic, functional mushroom coffees.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/66901_b3bb261db486a838_001.jpg

Keep reading... Show less

Inaugural runs of the award-winning and new white-label brands will allow the infused beverage expert to move ahead quickly with commercialization plans

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV) (OTCQB:BVNNF) (FSE:7BC) (“BevCanna” or the “Company”) is pleased to announce that it has successfully completed the R&D and trial production runs of its exclusively licenced award winning line of Keef Beverages and the white-label beverages the Company is producing for State B Beverages.

Keep reading... Show less

(TheNewswire)

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.

“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus,” said Michael Frank, Revive’s Chief Executive Officer.

Keep reading... Show less